FDA approves Incyte's once-daily Jakafi XR for blood disorders
Tweet Send to a Friend
Incyte Corporation (NASDAQ: INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR (ruxolitinib) extended-release tablets for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


